Latest publications Tumour Marker Group

Jørgensen KK, Goll GL, Sexton J, Bolstad N, Olsen IC, Asak Ø, Berset IP, Blomgren IM, Dvergsnes K, Florholmen J, Frigstad SO, Henriksen M, Hagfors J, Huppertz-Hauss G, Haavardsholm EA, Klaasen RA, Moum B, Noraberg G, Prestegård U, Rydning JH, Sagatun L, Seeberg KA, Torp R, Vold C, Warren DJ et al. (2020)
Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials
BioDrugs (in press)
DOI 10.1007/s40259-020-00438-7, PubMed 32965617

Kolstad A, Illidge T, Bolstad N, Spetalen S, Madsbu U, Stokke C, Blakkisrud J, Løndalen A, O'Rourke N, Beasley M, Jurczak W, Fagerli UM, Kaščák M, Bayne M, Obr A, Dahle J, Rojkjaer L, Pascal V, Holte H (2020)
Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma
Blood Adv, 4 (17), 4091-4101
DOI 10.1182/bloodadvances.2020002583, PubMed 32877524

Buhl S, Dorn-Rasmussen M, Brynskov J, Ainsworth MA, Bendtzen K, Klausen PH, Bolstad N, Warren DJ, Steenholdt C (2020)
Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease
Scand J Gastroenterol, 55 (8), 884-890
DOI 10.1080/00365521.2020.1786852, PubMed 32631131



More publications

 
Page visits: 779